Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LCZ · 1 trial · 1 indication
Change from baseline to Week 8 in mean sitting systolic blood pressure (msSBP)
| Arm | Type | Description |
|---|---|---|
| LCZ 200mg | ACTIVE_COMPARATOR | Oral administration, 1 tablet of LCZ 200 mg daily, 4 capsules of Amlodipine placebo daily. |
| LCZ 200mg + AML 2.5mg | EXPERIMENTAL | Oral administration, 1 tablet of LCZ 200 mg daily, 1 capsule of Amlodipine 2.5 mg daily and 3 capsules of Amlodipine placebo daily. |
| LCZ 200mg + AML 5mg | EXPERIMENTAL | Oral administration, 1 tablet of LCZ 200 mg daily, 2 capsules of Amlodipine 2.5 mg daily and 2 capsules of Amlodipine placebo daily. |
| LCZ 200mg + AML 10mg | EXPERIMENTAL | Oral administration, 1 tablet of LCZ 200 mg daily, 4 capsules of Amlodipine 2.5 mg daily. |
| Name | Type | Description |
|---|---|---|
| LCZ | DRUG | LCZ 200 mg |
| LCZ/AML 200 mg/2.5 mg | DRUG | LCZ/AML 200 mg/2.5 mg |
| LCZ/AML 200 mg/5 mg | DRUG | LCZ/AML 200 mg/5 mg |
| LCZ/AML 200 mg/10 mg | DRUG | LCZ/AML 200 mg/10 mg |
| Placebo | OTHER | Matching placebo of Amlodipine. |
Inclusion Criteria: Core Part) * Patients with grade 1 and 2 essential hypertension, untreated or currently taking antihypertensive therapy 1. Untreated patients \[either newly diagnosed with essential hypertension or those with a history of hypertension but have not been taking any antihyperte...
LCZ is an investigational small molecule being developed for the treatment of hypertension. It is currently in Phase 3 clinical development, though the specific trial for LCZ has been completed. The drug is being studied in patients with Grade 1 and 2 hypertension who are uncontrolled by LCZ696 monotherapy.
LCZ is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. Novartis is conducting clinical research on LCZ for the treatment of hypertension, with the drug currently in Phase 3 development.
LCZ is in Phase 3 clinical development for hypertension. The Phase 3 trial, NCT06236061, has been completed. This trial enrolled 718 participants and was a randomized, double-blind, active-controlled study conducted in Japan. LCZ remains investigational and has not been approved by regulatory authorities.
LCZ has one completed Phase 3 clinical trial, registered as NCT06236061. The study evaluated the efficacy and safety of LCZ696/Amlodipine in patients with Grade 1 and 2 hypertension uncontrolled by LCZ696 monotherapy. The trial enrolled 718 participants in Japan and was randomized, double-blind, and active-controlled.
LCZ is being studied in combination with LCZ696, as the trial evaluates LCZ696/Amlodipine. The drug name LCZ appears to refer to the combination product or a component of it. The completed Phase 3 trial specifically tested LCZ696/Amlodipine in hypertension patients uncontrolled by LCZ696 monotherapy.